For the relief of dry tickly coughs
AstraZeneca announced results from the Phase III SYGMA trials of Symbicort Turbuhaler (budesonide/formoterol) given as an anti-inflammatory reliever ‘as needed’...
New data from Novel START, an open-label trial designed to reflect real-world practice , has demonstrated the effectiveness of Symbicort...
Indicated for the treatment of primary dysmenorrhoea in women aged 15 to 50 years.
Asthma Symbicort is indicated in adults and adolescents (12 years and older) for the regular treatment of asthma, where use of a combination (inhaled corticosteroid and long-acting β 2 adrenoceptor agonist) is appropriate: - patients not adequately controlled with inhaled corticosteroids and “as needed” inhaled short-acting β 2 adrenoceptor agonists. or - patients already adequately controlled on both inhaled corticosteroids and long-acting β 2 adrenoceptor agonists.
BENYLIN Children's Chesty Coughs is an expectorant for the symptomatic relief of acute productive (chesty) coughs.
Asthma Symbicort Turbohaler is indicated in adults and adolescents (12 years and older) for the regular treatment of asthma, where use of a combination (inhaled corticosteroid and long-acting β 2 adrenoceptor agonist) is appropriate: - patients not adequately controlled with inhaled corticosteroids and as needed inhaled short-acting β 2 adrenoceptor agonists. or - patients already adequately controlled on both inhaled corticosteroids and long-acting β 2 adrenoceptor agonists. Symbicort Turbohaler is also indicated as reliever therapy for adults and adolescents (12 years and older) with mild asthma. Chronic Obstructive Pulmonary Disease (COPD) Symbicort Turbohaler is indicated in adults, aged 18 years and older, for the symptomatic treatment of patients with COPD with forced expiratory volume in 1 second (FEV 1 ) <70% predicted normal (post bronchodilator) and an exacerbation history despite regular bronchodilator therapy (see also section 4.4).
For the relief of occasional constipation.
BENYLIN CHILDREN'S NIGHT COUGHS is indicated for the relief of cough and its congestive symptoms, runny nose and sneezing, and in the treatment of hay fever and other allergic conditions affecting the upper respiratory tract. It is specially formulated for children and contains no artificial dyes or sucrose.
Fobumix Easyhaler is indicated in adults 18 years of age and older only. Asthma Fobumix Easyhaler 160 micrograms/ 4.5 micrograms is indicated for the regular treatment of asthma where use of a combination (inhaled corticosteroid and long-acting β 2 -adrenoceptor agonist) is appropriate: - patients not adequately controlled with inhaled corticosteroids and “as needed” inhaled short-acting β 2 -adrenoceptor agonists. or - patients already adequately controlled on both inhaled corticosteroids and long-acting β 2 -adrenoceptor agonists. Chronic Obstructive Pulmonary Disease (COPD) Fobumix Easyhaler 160 micrograms/ 4.5 micrograms is indicated in adults, aged 18 years and older, for the symptomatic treatment of patients with COPD with FEV 1 < 70% predicted normal (post-bronchodilator) and an exacerbation history despite regular bronchodilator therapy (see also section 4.4).